CD8A and neoplasm: The combination therapy of PIK-93 and anti–PD-L1 antibodies significantly increased both CD4+ and CD8+ TIL infiltration into the TME, suggesting that the combination therapy attenuates immunosuppression and enhances tumor growth inhibition in human PBMC CDX mouse models (H1975) and mouse syngeneic tumor models (CT26).